In this edition of The Upside, Lou Basenese sits down with Arun Swaminathan, CEO of Coya Therapeutics, a biotech targeting chronic inflammation in neurodegenerative disease. Coya’s approach focuses on restoring immune balance rather than simply treating symptoms in conditions like Alzheimer’s and ALS. Swaminathan outlines why this strategy could open a new treatment paradigm – and why investors may be overlooking its long-term potential in a $10B+ market.